| Literature DB >> 25537361 |
Noor Aa Giesbertz1, Annelien L Bredenoord1, Johannes Jm van Delden1.
Abstract
The inclusion of children's samples in biobanks brings forward specific ethical issues. Guidelines indicate that children should be involved in the consent procedure. It is, however, unclear how to allocate an appropriate role for children. Knowledge of current practice will be helpful in addressing this issue. Therefore, we conducted an international multiple-case study on the child's role in consent procedures in pediatric biobanks. Four biobanks were included: (1) LifeLines, (2) Prevention and Incidence of Asthma and Mite Allergy (PIAMA), (3) Young-HUNT3 and (4) the Oxford Radcliffe Biobank contribution to the Children's Cancer and Leukaemia Group tissue bank (ORB/CCLG). Four themes linked to the child's role in the consent procedure emerged from the multiple-case study: (1) motives to involve the child, (2) informing the child, (3) the role of dissent, assent and consent and (4) voluntariness of children to participate. We conclude that biobank characteristics influence the biobank's motives to include children in the consent procedure. Moreover, the motives to include children influence how the children are involved in the consent procedure, and the extent to which children are able to make voluntary decisions as part of the consent procedure. This insight is valuable when designing pediatric biobank governance.Entities:
Mesh:
Year: 2014 PMID: 25537361 PMCID: PMC4538194 DOI: 10.1038/ejhg.2014.267
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246
Interview respondents' characteristics
| Biobank official | 11 |
| Research nurse/assistant | 6 |
| Researcher | 3 |
| Parent | 3 |
| Child | 6 |
Case characteristics
| Country | Netherlands | Netherlands | Norway | United Kingdom |
| Type | A three-generation population based cohort study | Birth cohort study | Cross-sectional survey, with possibility for follow-up | Tissue bank with residual tumor samples |
| Participants | Aim is to include 165 000 participants, of which 15 000 children 0–18 years. Official number will follow in 2014. Children included between 2010 and 2013 | Baseline consists of 3963 children born between 1996 and 1997 | 8677 adolescents (13–19 years) included between 2006 and 2008 | Patients from the John Radcliffe hospital with a suspected diagnosis of a pediatric-type solid cancer. The cooperation started in 2009. Estimation: 10–30 patients per year provide consent |
| Research protocol | Questionnaire parent, questionnaire children ≥13 years, clinical tests children ≥8 years. Follow- up every 5 years | Part 1: Research aimed at mite allergy and asthma. Children followed up to 8 years with questionnaires for parents and clinical tests in subgroups at 1, 4 and 8. Residual blood from the newborn screening was used. Part 2: Extension of follow-up to 16 years. Research goal broadened to chronic diseases. Clinical tests (at 11/12 years and 15/16 years) and questionnaires parents and children | Questionnaires, clinical tests and short interview at school. Phase 2 studies in subgroups: physical fitness, acne, sight or social anxiety | Residual tissue (from a diagnostic or therapeutic sampling procedure) is stored in the tissue bank. Blood sample taken during routine blood tests |
| Biological material | Blood and urine samples | Blood samples, nasal epithelial cells, DNA swabs | Buccal swabs | Tumor tissue and blood samples |
| Inclusion | Through parents who participate in LifeLines | Through pregnant women | Through schools | Through hospital staff |
Description of consent procedures
| LifeLines | Parents participating in LifeLines receive an invitation for their child to participate. After parental agreement, the family receives a letter, an information folder for parents and an informed consent form that must be signed by at least one parent. A children's information brochure is added for children ≥8 years. An informed consent form for the child is added for children ≥12 years. By returning the signed informed consent form(s) to Lifelines, parents receive a questionnaire and/or an invitation for screening of the child on location |
| PIAMA | For the first part of the PIAMA project, pregnant women must provide written consent for the inclusion of their child. Both parents must provide written consent for clinical tests at 1, 4 and 8 years old. Parents need to provide additional written consents for, among other things, the use of residual blood from the newborn screening (for an IgE measurement) and additional measurements in former blood samples (glucose, HbA1c, cholesterol). For the second part of the PIAMA project, families receive, when the children are 11/12 years, an invitation letter, information material (both for parents and children), a consent form for the parents and a separate form for children ≥12 years. The signed consent form(s) must be returned to PIAMA. When the children are 15/16 years, families receive two invitation letters (one addressed to the parent and one to the child), combined information material for parents and child, a combined consent form that needs to be signed by the parents and child. One parent may sign at home, the other parent and the child must sign at location after an informed consent conversation |
| Young-HUNT3 | HUNT provides information to the schools/teachers and the school board must give permission for participation of the school in HUNT. Subsequently, the teachers inform the students in the class and hand out the information brochure for the children to take home and to discuss it with their parents. Consent must be signed by at least one of the parents and returned to the school. The child needs to sign a consent form at the time of the questionnaire (in the class). Before and after the clinical tests, the nurse asks whether the children have questions. If children want to participate, but the parents do not give consent, the children may participate in the questionnaire/tests; however, in that case the data will not be saved |
| ORB/CCLG | First, a consultant or research nurse gives a verbal explanation to patients and parents. Thereafter, written information is handed out (both for the child and the parents). Later, patient and parents must sign the consent forms. It depends on the child's capacities and wishes whether the child and/or the parents must sign an assent/consent form |